glp-1 gastric stasis law firm in west virginia The Wagner glp-1 gastric stasis legal team

Lawsuits argue that drug manufacturers failed to properly warn diabetes patients that these medications may increase the risk of vision problems

The GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Market is undergoing a paradigm shift, transforming from a niche therapeutic class primarily used in type 2 diabetes management to a multi-billion-dollar market at the heart of the global obesity epidemic

Do not try to catch up by doubling the next dose

Starting a medication that suppresses appetite and slows gastric emptying during this adjustment period can create complications that are easily avoided by waiting a few more weeks